162758-35-2

Basic information

• Product Name: 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid
• Synonyms: 5-(4-CHLORO-PHENYL)-1-(2,4-DICHLORO-PHENYL)-4-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID;RIMONABANT CARBOXYLIC ACID;5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHY-1H-PYRAZOLE-3-CARBOXYLIC ACID;RIMONABANTACID;5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid;1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-;Rimonabant carboxylic acid ,99%
• CAS NO: 162758-35-2
• Molecular Formula: C₁₇H₁₁Cl₃N₂O₂
• Molecular Weight: 381.64
• Product Categories: pharmacetical
• Mol File: 162758-35-2.mol
• Article Data: 40

Chemical Properties

• Melting Point: 202-203 °C
• Boiling Point: 551.208 °C at 760 mmHg
• Flash Point: 287.161 °C
• Appearance: /
• Density: 1.48
• Vapor Pressure: 5.52E-13mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 3.33±0.34(Predicted)
• CAS DataBase Reference: 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid(162758-35-2)
• EPA Substance Registry System: 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid(162758-35-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 162758-35-2(Hazardous Substances Data)

Usage

Chemical Properties

White fine solid powder

Uses

Different sources of media describe the Uses of 162758-35-2 differently. You can refer to the following data:
1. 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic Acid is used in the preparation of biarylpyrazole based derivatives as cannabinoid CB1 receptor antagonists. It is metabolite M9 of Rimonabant (R517800), an antiobesity agent.
2. 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic Acid is used in the preparation of biarylpyrazole based derivatives as cannabinoid CB1 receptor antagonists. It is metabolite M9 of Rimonabant (R517800), an antiobesity agent.

InChI:InChI=1/C17H11Cl3N2O2/c1-9-15(17(23)24)21-22(14-7-6-12(19)8-13(14)20)16(9)10-2-4-11(18)5-3-10/h2-8H,1H3,(H,23,24)

Upstream product

• 1012314-40-7 ethyl 4-(4-chlorophenyl)-3-methyl-4-oxydo-2-oxobuten-3-oate lithium salt 
• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 
• 6285-05-8 4'-chloropropiophenone 
• 95-92-1 oxalic acid diethyl ester 
• 13123-92-7 (2,4-dichlorophenyl)hydrazine 
• 169544-41-6 4-(4-chlorophenyl)-3-methyl-2,4-dioxobutyric acid ethyl ester 
• 170937-37-8 4-(4-chlorophenyl)-2-[(2,4-dichlorophenyl)-hydrazono]-3-methyl-4-oxobutyric acid ethyl ester 
• 944154-78-3 C₁₉H₁₈Cl₃N₂O₃^(1-)*Li⁽¹⁺⁾ 
• 192702-54-8 5-(4-chloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1193-72-2 1-bromo-2,4-dichlorobenzene 
• 68716-47-2 2,4-dichlorophenylboronic acid 
• 1030616-35-3 phenyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylate 
• 2213-43-6 1-Aminopiperidine 
• 168272-78-4 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid methyl ester 

Downstream Products

• 168273-05-0 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl chloride 
• 614726-85-1 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1016557-47-3 N-butanoyl-N'-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl]-hydrazine 
• 949522-87-6 C₁₉H₁₅Cl₃N₄O₂ 
• 1020796-04-6 C₂₂H₁₅Cl₃N₄O₃ 
• 1020796-28-4 C₂₂H₁₅Cl₃N₄O₂S 
• 1020800-97-8 C₂₇H₂₁Cl₃N₄O₂ 
• 1020800-67-2 C₂₇H₂₀Cl₄N₄O₂ 
• 1020797-88-9 C₂₄H₂₅Cl₃N₄O₂ 
• 1020804-81-2 C₂₂H₁₆Cl₃F₃N₄O₂ 
• 1020800-16-1 C₂₃H₂₃Cl₃N₄O₂ 
• 1020801-94-8 C₂₅H₂₇Cl₃N₄O₂ 
• 1020801-53-9 C₂₇H₂₂Cl₄N₄O₂ 
• 1020795-56-5 N'-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl)isonicotinohydrazide 

Relevant articles and documents

An improved synthesis of rimonabant: Anti-obesity drug

A novel, cost-effective, and efficient process was developed for the large-scale synthesis of Rimonabant 1, an anti-obesity drug. The process involves the conversion of 4-chloro propiophenone 2 to cyclized acid 6 as a key intermediate that afforded Rimonabant 1 in good yield.

Novel 1,5-diaryl pyrazole-3-carboxamides as selective COX-2/sEH inhibitors with analgesic, anti-inflammatory, and lower cardiotoxicity effects

COX-2 selective drugs have been withdrawn from the market due to cardiovascular side effects, just a few years after their discovery. As a result, a new series of 1,5-diaryl pyrazole carboxamides 19–31 was synthesized as selective COX-2/sEH inhibitors wit

Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes

The cannabinoid-1 receptor (CB1R) inverse agonist SR141716A has proven useful for study of the endocannabinoid system, including development of divalent CB1R ligands possessing a second functional motif attached via a linker unit. These have predominantly employed the C3 position of the central pyrazole ring for linker attachment. Despite this precedent, a novel series of C3-linked CB1R-D2R divalent ligands exhibited extremely high affinity at the D2R, but only poor affinity for the CB1R. A systematic linker attachment point survey of the SR141716A pharmacophore was therefore undertaken, establishing the C5 position as the optimal site for linker conjugation. This linker attachment survey enabled the identification of a novel divalent ligand as a lead compound to inform ongoing development of high-affinity CB1R molecular probes.

Discovery of rimonabant and its potential analogues as anti-TB drug candidates

Rimonabant and its analogues have been synthesized in moderate to good yields using a simple synthetic route. All the newly synthesized compounds were subjected to in vitro screening against M. tuberculosis and M. smegmatis. The most potent analogue JMG-14 exhibits MIC value of 3.13 compared to 3.25 and 50 μ/ml for ethambutol and pyrazinamide, respectively. The molecular docking reveals that pyrazole ring, number and position of halogen atoms play a crucial role in deciding interactions with MTCYP-121. These findings open up a new avenue in the search of potent anti-TB drugs with rimonabant and its novel analogue JMG-14 as lead molecules.